Merck to Acquire Themis
Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately-held Themis.
Merck Media:
Patrick Ryan
+1 (201) 452-2409
Ian McConnell
+1 (973) 901-5722
Themis Media & Investors
Gretchen Schweitzer
+49 172 861 8540
Jacob Verghese
+49 89 2388 7731
Merck Investors:
Peter Dannenbaum
+1 (908) 740-1037
Michael DeCarbo
+1 (908) 740-1807
Read Original Article: Merck to Acquire Themis »
